Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE 2026 FIRST EXTRAORDINARY GENERAL MEETING, THE 2026 FIRST A SHAREHOLDERS' CLASS MEETING AND THE 2026 FIRST H SHAREHOLDERS' CLASS MEETING HELD ON FRIDAY, 27 FEBRUARY 2026

The board (the "**Board**") of directors (the "**Directors**") of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") is pleased to announce the poll results of the 2026 first extraordinary general meeting (the "**EGM**"), the 2026 first class meeting of holders of A shares of the Company (the "**A Shareholders' Class Meeting**") and the 2026 first class meeting of holders of H shares of the Company (the "**H Shareholders' Class Meeting**") (collectively, the "**Meetings**") held at Sky Fortune Boutique Hotel Shanghai, No. 358 Hong Xu Road, Shanghai, the PRC at 1:30 p.m. on Friday, 27 February 2026.

References are made to the notice of the EGM, the notice of the H Shareholders' Class Meeting and the circular (the "**Circular**") of the Company, all dated 4 February 2026. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the record dates of the Meetings, (i) the total number of the issued shares of the Company (the "**Shares**") was 2,670,429,325 Shares, comprising 2,118,488,825 A Shares and 551,940,500 H Shares; (ii) holders of 2,639,554,073 Shares (or by authorised proxies) were entitled to attend and vote on the resolutions proposed at the EGM; and (iii) holders of 2,098,582,573 A Shares (or by authorised proxies) and 540,971,500 H Shares (or by authorised proxies) were entitled to attend and vote on the resolutions proposed at the A Shareholders' Class Meeting and H Shareholders' Class Meeting, respectively. There were no Shares entitling the Shareholders to attend and vote only against the resolutions at the Meetings.

As at the record dates of the Meetings, (i) Ms. Guan Xiaohui, an executive Director, held 267,743 A Shares and 25,000 H Shares, (ii) Mr. Wen Deyong, an executive Director, held 81,743 A Shares and 20,000 H Shares, (iii) Mr. Wang Kexin, an executive Director, held 303,516 A Shares and 20,000 H Shares, (iv) Mr. Chen Qiyu, a non-executive Director, held 114,075 A Shares, and (v) Ms. Feng Rongli, a senior management member of the Company, held 50,855 A Shares. Therefore, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin, Mr. Chen Qiyu and Ms. Feng Rongli (collectively owned 817,932 A Shares and 65,000 H Shares) who had an interest in the resolution in relation to the shareholdings of certain directors, senior management members of the Company and their affiliated parties in the company to be spun off (i.e. resolution no. 10 of the EGM), were required to and had abstained from voting on the resolution at the EGM. To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, save as disclosed above, no other Shareholder has any material interest in the resolutions proposed at the EGM, the A Shareholders' Class Meeting or the H Shareholders' Class Meeting and is required to abstain from voting at the EGM, the A Shareholders' Class Meeting or the H Shareholders' Class Meeting. No Shareholder has stated in the Circular his/her/its intention to vote against any resolution at the Meetings.

ATTENDANCE AT THE MEETINGS

(I) Attendance at the EGM:

Set out below are the details of the Shareholders and authorised proxies present at the EGM:

Number of Shareholders and authorised proxies		1,562
Including:	Number of A Shareholders	1,560
	Number of H Shareholders	2
Total number of Shares carrying voting rights (shares)		1,110,294,633
Including:	Total number of Shares carrying voting rights held by A Shareholders (shares)	966,487,915
	Total number of Shares carrying voting rights held by H Shareholders (shares)	143,806,718
Percentage of the total number of Shares carrying voting rights (%)		42.0637
Including:	Number of A Shares as a percentage of the total number of Shares carrying voting rights (%)	36.6156
	Number of H Shares as a percentage of the total number of Shares carrying voting rights (%)	5.4481

(II) Attendance at the A Shareholders' Class Meeting:

Set out below are the details of the A Shareholders and authorised proxies present at the A Shareholders' Class Meeting:

Number of A Shareholders and authorised proxies	1,560
Total number of A Shares carrying voting rights (shares)	966,487,915
Number of A Shares as a percentage of the total number of A Shares carrying voting rights of the Company (%)	46.0543

(III) Attendance at the H Shareholders' Class Meeting:

Set out below are the details of the H Shareholders and authorised proxies present at the H Shareholders' Class Meeting:

Number of H Shareholders and authorised proxies	1
Total number of H Shares carrying voting rights (shares)	143,794,718
Number of H Shares as a percentage of the total number of H Shares carrying voting rights of the Company (%)	26.5808

The Meetings were convened in compliance with the requirements of the Company Law and the Articles of Association, and were chaired by Mr. Chen Yuqing, the chairman of the Board of the Company. The Company has twelve (12) Directors in office, six (6) Directors of the Company, including four (4) executive Directors, namely Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wang Kexin and Mr. Liu Yi; two (2) independent non-executive Directors, namely Mr. Yu Tze Shan Hailson and Mr. Wang Quandi attended the Meetings.

In compliance with the requirements of the Hong Kong Listing Rules and Article 108 of the Articles of Association, BDO Limited, Grandall Law Firm (Shanghai)* (國浩律師(上海)事務所), the Company's PRC legal advisers and the Shareholders' representatives acted as the scrutineers for the vote-counting at each of the Meetings.

Note regarding the scope of work of BDO Limited: The poll results were subject to scrutiny by BDO Limited, Certified Public Accountants (Practising), whose work was limited to certain procedures requested by the Company to agree the poll results summary prepared by the Company to the poll forms collected and provided by the Company to BDO Limited. The work performed by BDO Limited in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants nor did it include the provision of any assurance or advice on matters of legal interpretation or entitlement to vote.

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE MEETINGS

(I) Poll results of the EGM:

All resolutions at the EGM were voted on by poll. The poll results (including those of the minority shareholders) in respect of the resolutions proposed at the EGM are as follows:

SPECIAL RESOLUTIONS			Number of valid votes		
			For	Against	Abstain
1.	To consider and approve the resolution in relation to the compliance of the spin-off of Fosun Adgenvax (a subsidiary of the Company) for listing on the Main Board of the Hong Kong Stock Exchange with the requirements under the relevant laws and regulations.	Shareholders	1,108,289,583 (99.8194%)	1,781,800 (0.1605%)	223,250 (0.0201%)
		Minority shareholders only	140,865,128 (98.5966%)	1,781,800 (1.2471%)	223,250 (0.1563%)
2.	To consider and approve the resolution in relation to the plan of the spin-off of Fosun Adgenvax (a subsidiary of the Company) for initial public offering of H shares and its listing on the Main Board of the Hong Kong Stock Exchange.	Shareholders	1,108,242,883 (99.8154%)	1,813,500 (0.1633%)	235,750 (0.0213%)
		Minority shareholders only	140,818,428 (98.5656%)	1,813,500 (1.2694%)	235,750 (0.1650%)
3.	To consider and approve the proposal on the spin-off of Fosun Adgenvax (a subsidiary of the Company) for listing on the Main Board of the Hong Kong Stock Exchange.	Shareholders	1,108,224,083 (99.8137%)	1,851,700 (0.1668%)	216,350 (0.0195%)
		Minority shareholders only	140,799,628 (98.5525%)	1,851,700 (1.2961%)	216,350 (0.1514%)
4.	To consider and approve the resolution in relation to the compliance of the spin-off of Fosun Adgenvax (a subsidiary of the Company) for listing on the Main Board of the Hong Kong Stock Exchange with the Spin-off Rules.	Shareholders	1,108,285,083 (99.8192%)	1,816,200 (0.1636%)	190,850 (0.0172%)
		Minority shareholders only	140,860,628 (98.5952%)	1,816,200 (1.2712%)	190,850 (0.1336%)
5.	To consider and approve the resolution in relation to the purpose, commercial rationale, necessity and feasibility of the Proposed Spin-off Listing.	Shareholders	1,108,182,383 (99.8100%)	1,911,200 (0.1721%)	198,550 (0.0179%)
		Minority shareholders only	140,757,928 (98.5233%)	1,911,200 (1.3377%)	198,550 (0.1390%)

SPECIAL RESOLUTIONS			Number of valid votes		
			For	Against	Abstain
6.	To consider and approve the resolution in relation to the Company's maintenance of independence and continuous operating capability.	Shareholders	1,108,326,283 (99.8229%)	1,720,300 (0.1549%)	245,550 (0.0222%)
		Minority shareholders only	140,901,828 (98.6240%)	1,720,300 (1.2041%)	245,550 (0.1719%)
7.	To consider and approve the resolution in relation to Fosun Adgenvax possessing the corresponding capabilities for standardized operations.	Shareholders	1,108,270,283 (99.8179%)	1,768,600 (0.1593%)	253,250 (0.0228%)
		Minority shareholders only	140,845,828 (98.5848%)	1,768,600 (1.2379%)	253,250 (0.1773%)
8.	To consider and approve the resolution in relation to the benefits of the spin-off of Fosun Adgenvax (a subsidiary of the Company) for listing on the Main Board of the Hong Kong Stock Exchange in safeguarding the legitimate rights and interests of shareholders and creditors.	Shareholders	1,108,233,283 (99.8146%)	1,852,600 (0.1669%)	206,250 (0.0185%)
		Minority shareholders only	140,808,828 (98.5589%)	1,852,600 (1.2967%)	206,250 (0.1444%)
9.	To consider and approve the resolution in relation to the completeness and compliance of statutory procedures for the Proposed Spin-off Listing, and the validity of submitted legal documents.	Shareholders	1,108,255,883 (99.8166%)	1,773,900 (0.1598%)	262,350 (0.0236%)
		Minority shareholders only	140,831,428 (98.5747%)	1,773,900 (1.2416%)	262,350 (0.1837%)
10.	To consider and approve the resolution in relation to the shareholdings of certain directors, senior management members of the Company and their affiliated parties in the company to be spun off.	Shareholders	1,108,137,883 (99.8060%)	1,921,000 (0.1730%)	233,250 (0.0210%)
		Minority shareholders only	140,713,428 (98.4921%)	1,921,000 (1.3446%)	233,250 (0.1633%)
11.	To consider and approve the resolution in relation to the authorisation to the Board or its authorised persons to deal with matters related to the Proposed Spin-off Listing.	Shareholders	1,108,196,383 (99.8112%)	1,870,100 (0.1684%)	225,650 (0.0204%)
		Minority shareholders only	140,771,928 (98.5331%)	1,870,100 (1.3090%)	225,650 (0.1579%)

SPECIAL RESOLUTIONS			Number of valid votes		
			For	Against	Abstain
12.	To consider and approve the resolution in relation to the provision of assured entitlements to H Shareholders of the Company only in connection with the spin-off of Fosun Adgenvax (a subsidiary of the Company) for listing on the Main Board of the Hong Kong Stock Exchange.	Shareholders	1,081,638,104 (97.4192%)	28,403,379 (2.5582%)	250,650 (0.0226%)
		Minority shareholders only	114,213,649 (79.9437%)	28,403,379 (19.8809%)	250,650 (0.1754%)

Pursuant to the applicable laws, regulations and regulatory documents, (i) resolution no. 10 requires approval by more than half of the voting rights held by the minority shareholders present at the EGM; and (ii) resolutions no. 1, 2, 3, 4, 5, 6, 7, 8, 9, 11 and 12 require approval by at least two-thirds of the voting rights held by minority shareholders present at the EGM. "Minority shareholders" refer to the other Shareholders excluding the Directors, senior management, and Shareholders individually or collectively holding 5% or more of the Shares pursuant to the PRC laws, regulations and regulatory provisions.

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the EGM and more than half of the votes from the minority shareholders (including their proxies) attending the EGM were cast in favour of the resolution no. 10 proposed at the EGM, the resolution was duly passed as a special resolution.

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the EGM and more than two-thirds of the votes from the minority shareholders (including their proxies) attending the EGM were cast, respectively, in favour of resolutions no. 1, 2, 3, 4, 5, 6, 7, 8, 9, 11 and 12 proposed at the EGM, each of the resolutions was duly passed as a special resolution.

(II) Poll results of the A Shareholders' Class Meeting:

The resolution proposed at the A Shareholders' Class Meeting was voted on by poll. The poll results (including those of the minority shareholders) in respect of the resolution proposed at the A Shareholders' Class Meeting are as follows:

SPECIAL RESOLUTION			Number of valid votes		
			For	Against	Abstain
1.	To consider and approve the resolution in relation to the provision of assured entitlements to H Shareholders of the Company only in connection with the spin-off of Fosun Adgenvax (a subsidiary of the Company) for listing on the Main Board of the Hong Kong Stock Exchange.	Shareholders	937,926,086 (97.0448%)	28,312,179 (2.9294%)	249,650 (0.0258%)
		Minority shareholders only	48,035,131 (62.7115%)	28,312,179 (36.9625%)	249,650 (0.3260%)

Pursuant to the applicable laws, regulations and regulatory documents, the resolution requires approval by at least two-thirds of the voting rights held by minority shareholders present at the A Shareholders' Class Meeting.

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the A Shareholders' Class Meeting were cast in favour of this resolution while less than two-thirds of the votes from the minority shareholders (including their proxies) attending the A Shareholders' Class Meeting were cast in favour of the resolution proposed at the A Shareholders' Class Meeting, the resolution was not passed as a special resolution at the A Shareholders' Class Meeting.

(III) **Poll results of the H Shareholders' Class Meeting:**

The resolution proposed at the H Shareholders' Class Meeting was voted on by poll. The poll results in respect of the resolution proposed at the H Shareholders' Class Meeting are as follows:

SPECIAL RESOLUTION		Number of valid votes		
		For	Against	Abstain
1.	To consider and approve the resolution in relation to the provision of assured entitlements to H Shareholders of the Company only in connection with the spin-off of Fosun Adgenvax (a subsidiary of the Company) for listing on the Main Board of the Hong Kong Stock Exchange.	143,793,718 (99.9993%)	0 (0.000%)	1,000 (0.0007%)

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the H Shareholders' Class Meeting were cast in favour of this resolution, the resolution was duly passed as a special resolution.

The relevant resolution in relation to the provision of assured entitlements to H Shareholders of the Company only in connection with the spin-off of Fosun Adgenvax (a subsidiary of the Company) for listing on the Main Board of the Hong Kong Stock Exchange was proposed to the Shareholders to be considered and approved as special resolution by Shareholders at the EGM, the A Share Class Meeting and the H Share Class Meeting, respectively. Such resolution was duly approved at the EGM and the H Shareholders' Class Meeting, respectively. However, such resolution was not approved at the A Shareholders' Class Meeting, and the subject matters underlying such resolution were deemed considered but not approved. Therefore, the assured entitlements would not be provided to any A Shareholders or H Shareholders of the Company under the Proposed Spin-off Listing. For the avoidance of doubt, it is hereby clarified that the failure in passing the resolution will not affect the final implementation of the Proposed Spin-off Listing of Fosun Adgenvax on the Main Board of the Hong Kong Stock Exchange.

CERTIFICATION

As certified by and stated in the legal opinion issued by Grandall Law Firm (Shanghai)* (國浩律師(上海)事務所), the Company's PRC legal advisers, the convening and holding of the Meetings are in compliance with the requirements of the relevant laws, administrative regulations, the Rules of General Meetings of Listed Companies and the Articles of Association, the qualifications of the attendees of the Meetings and the convener are legally valid, and the voting procedures and voting results of the Meetings are legally valid.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
27 February 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *For identification purposes only*